LGM
PRLD icon

Logos Global Management’s Prelude Therapeutics PRLD Stock Holding History

Logos Global Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-400,000
Closed -$12.5M – 75
2021
Q3 		$12.5M Hold
400,000
– – 0.9% 29
2021
Q2 		$11.5M Buy
+400,000
New +$14.2M 0.96% 32

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Logos Global Management's PRLD Position: Q4 2021 in Review

Logos Global Management sold out of Prelude Therapeutics (PRLD) in Q4 2021, closing a stake of 400,000 shares — an estimated $12.5M sold.

Logos Global Management first reported a position in PRLD in Q2 2021 and held it in 2 quarters. The position peaked at $12.5M in Q3 2021. 75 funds tracked by Wall St. Rank hold PRLD as of Q4 2021.

  • Logos Global Management reported no remaining Prelude Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Logos Global Management sold 400,000 Prelude Therapeutics shares in Q4 2021, an estimated $12.5M.
  • Logos Global Management first reported a position in Prelude Therapeutics in Q2 2021 and held it in 2 quarters.
  • Logos Global Management's Prelude Therapeutics position peaked at $12.5M in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2021.

Based on Logos Global Management's 13F filing for Q4 2021, filed 14 Feb 2022.